학술논문
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Document Type
article
Author
Julie M. Vose; Kai Fu; Lu Wang; Adnan Mansoor; Douglas Stewart; Hongxia Cheng; Lynette Smith; Ji Yuan; Hina Naushad Qureishi; Brian K. Link; Melissa H. Cessna; Paul M. Barr; Brad S. Kahl; Matthew S. Mckinney; Nadia Khan; Ranjana H. Advani; Peter Martin; Andre H. Goy; Tycel J. Phillips; Amitkumar Mehta; Manali Kamdar; Michael Crump; Barbara Pro; Christopher R. Flowers; Caron A. Jacobson; Sonali M. Smith; Deborah M. Stephens; Veronika Bachanova; Zhaohui Jin; Shishou Wu; Francisco Hernandez-Ilizaliturri; Pallawi Torka; Andrea Anampa-Guzmán; Farshid Kashef; Xing Li; Sunandini Sharma; Timothy C. Greiner; James O. Armitage; Matthew Lunning; Dennis D. Weisenburger; Robert G. Bociek; Javeed Iqbal; Guohua Yu; Chengfeng Bi; the North American Mantle Cell Lymphoma Consortium
Source
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-12 (2023)
Subject
Language
English
ISSN
1756-8722
Abstract
Abstract Background Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for a more accurate prediction of patient outcomes. Methods The North American Mantle Cell Lymphoma Project is a multi-institutional collaboration of 23 institutions across North America to evaluate and refine prognosticators for front-line therapy. A total of 586 MCL cases diagnosed between 2000 and 2012 are included in this study. A comprehensive retrospective analysis was performed on the clinicopathological features, treatment approaches, and outcomes of these cases. The establishment of novel prognostic models was based on in-depth examination of baseline parameters, and subsequent validation in an independent cohort of MCL cases. Results In front-line strategies, the use of hematopoietic stem cell transplantation was the most significant parameter affecting outcomes, for both overall survival (OS, p